Under the terms of the transaction, Stiefel will utilize Allergan’s proprietary technology and tazarotene in several ways. Stiefel will co-promote Allergan’s Tazorac (tazarotene) to dermatologists in the US. Stiefel also will capitalize on its existing patent-protected technology and Allergan’s tazarotene compound to bring unique therapeutic options to market for a common dermatological disease.
Bill Humphries, chief commercial officer of Stiefel, said: “Tazorac will provide the perfect complement to our acne portfolio, which also includes Duac, and it will allow Stiefel to offer best-in-class topical acne treatments to our customers. Given our long-standing and well-established presence in the dermatology arena, we will be able make an immediate and important impact with Tazorac.”